SADIA CHEEMA: Open Payments
NPI 1144873043 · GAMBRILLS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,038 in 94 payments from 17 companies in 2025. Trend: 2023 $764 · 2024 $1,398 · 2025 $2,038
Food & beverage: $2,029Education: $9
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $311 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $293 |
| Alkermes, Inc. | 15 | $259 |
| Indivior Inc. | 8 | $218 |
| Lundbeck LLC | 10 | $210 |
| Vanda Pharmaceuticals Inc. | 7 | $173 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Supernus Pharmaceuticals, Inc. | 5 | $103 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
Products named: VRAYLAR, CAPLYTA, REXULTI, SUBLOCADE, HETLIOZ, ARISTADA, AUSTEDO XR, Qelbree.
Industry payments across MD — which companies pay providers there.
